$8.160
+0.020 (+0.25%)Al cierre
- High
- 8.180
- Open
- 8.150
- VWAP
- 8.14
- Vol
- 9.34M
- Mkt Cap
- 132.57M
- Low
- 8.070
- Amount
- 76.02M
- EV/EBITDA, TTM
- -0.18
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Analyst Ratings (6)
Wells Fargo
$6
2025-03-27
Wells Fargo
2025-03-27
Precio objetivo
$6
Canaccord Genuity
$28
2025-03-17
Canaccord Genuity
2025-03-17
Precio objetivo
$28
HC Wainwright & Co.
$10
2025-03-14
HC Wainwright & Co.
2025-03-14
Precio objetivo
$10
HC Wainwright & Co.
$10
2025-02-26
HC Wainwright & Co.
2025-02-26
Precio objetivo
$10
HC Wainwright & Co.
$10
2024-11-11
HC Wainwright & Co.
2024-11-11
Precio objetivo
$10
Métricas de valoración
Cronología de eventos
Noticias
7.005-15GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders
8.505-15GlobenewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq - SSBK)
9.505-08PRnewswireRegulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
7.005-06PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders
4.005-01BenzingaThis Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
RGLS FAQ — answered by Alphio AI
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, farabursen, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. The microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. The ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
6 analysts cover RGLS: 1 rate it Buy, 5 Hold and 0 Sell. The average price target is 8.50.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.